Logo Image
|Articles|October 21, 2020

AstraZeneca COVID-19 Vaccine Volunteer Dies

The participant was taking a placebo and the trial will continue according to initial reports.


A Brazilian participant in the AstraZeneca and Oxford University COVID-19 vaccine trial has died, according to the Brazilian health authority Anvisa and reported by Reuters.

It was also reported the trial was going to continue according to Oxford University. “There have been no concerns about safety of the clinical trial,” according to a statement that was made by Oxford.

The Brazilian newspaper O Globo reported that the volunteer had been given a placebo.

Back in September, the AstraZeneca/Oxford University COVID-19 vaccine trial being held in the United Kingdom was halted after a participant suffered an adverse event. The trial was resumed in the UK, but has not done so in the United States.

The US Food and Drug Administration (FDA) started an investigation into the adverse event.

As this story is evolving, check back for further updates.

Related to this article

View more
FAQ: West Nile Virus
FAQ: West Nile Virus
After 2 adults died of West Nile virus in central North Carolina this month, this FAQ explains how the mosquito-borne virus spreads, who faces the greatest risk of severe neuroinvasive disease, and how clinicians can diagnose, manage, and help prevent infection when no vaccine or antiviral treatment exists.
Read more
NFID Survey Finds Respiratory Vaccine Gap Driven by Lack of Clarity, Not Hesitancy
NFID Survey Finds Respiratory Vaccine Gap Driven by Lack of Clarity, Not Hesitancy
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
Read more